Problem: Levels of placental growth factor (PlGF) peak during third trimester of pregnancy, a time when women are at increased risk of virus-induced morbidity. We hypothesized PlGF might contribute to an exaggerated inflammatory response to Toll-like receptor (TLR) activation.
| INTRODUCTION
During pregnancy, the maternal immune system balances the development of tolerance to foreign (paternal) antigens with maintaining immune surveillance to pathogenic stimuli. However, pregnant women are often at an increased risk of infectious complications leading to potentially devastating effects on both maternal and fetal morbidity and mortality. 1, 2 For example, during the 2009 H1N1 influenza pandemic, pregnancy was associated with an eightfold increased risk of death. 3 While bacterial complications are known to occur in the setting of severe influenza infections, in the reported series of early deaths among pregnant women with influenza, there was a lack of evidence of secondary bacterial pneumonia and rather an increased prevalence of inflammatory complications such as acute respiratory distress syndrome (ARDS), [4] [5] [6] suggesting that the response to the viral infection per se contributed to overall morbidity and mortality. The highest incidence of death occurred in pregnant women during their third trimester, [7] [8] [9] a time point at which levels of a number of pregnancy-associated factors peak, including placental growth factor (PlGF), 10 a member of the vascular endothelial growth factor (VEGF) family.
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Responses of the innate immune system to viral (and other) infections are controlled in large part by Toll-like receptor (TLR) signaling pathways in mononuclear phagocytes. The recognition of conserved microbial signatures, and endogenous molecules produced as a result of tissue injury and/or inflammation, by TLRs plays a critical role in inducing the expression of pro-inflammatory cytokine genes, thereby activating both the innate and adaptive immune responses. [12] [13] [14] [15] These processes must be tightly regulated, because without feedback mechanisms designed to suppress such responses in a timely fashion, the resulting unrestrained inflammation can lead to life-threatening complications. [16] [17] [18] [19] Indeed, inappropriate immune responses play an important role in regulation of pregnancy outcomes. 1, 2 Evidence of enhanced activation of the innate immune system has been demonstrated in pregnancy, including the expression of monocyte phenotypic activation markers, [20] [21] [22] [23] and increased monocyte production of intracellular reactive oxygen species. 20 Others have observed increased cytokine production by mononuclear phagocytes of pregnant women. 22, 24, 25 The factors contributing to viral-induced morbidity and mortality in pregnancy may include a variety of angiogenic stimuli. [26] [27] [28] [29] PlGF is one such factor. Specifically, pathologic increases in PlGF have been described in diverse clinical settings characterized by an increased risk of inflammatory complications, including the hemoglobinopathies, inflammatory arthritis, inflammatory bowel disease, and allogeneic hematopoietic stem cell transplantation. [30] [31] [32] [33] [34] However, studies linking
PlGF to tumor necrosis factor-alpha (TNF) production have reported the effect of PlGF on TNF transcript abundance but have not included studies on TNF protein levels. 30, 31 In light of the clear tie between TNF levels and H1N1-induced mortality, 35 we sought to determine whether PlGF influenced TNF gene expression under conditions that mimic viral infection of mononuclear phagocytes.
We focused largely on TLR-7/8 activation, as these specific TLRs are known to be required for the recognition of single-stranded viruses such as influenza. 36 Using primary mononuclear phagocytes, we determined that PlGF alone did not influence TNF secretion by normal human monocytes, and that PlGF has a minimal effect on TNF messenger RNA (mRNA) production on its own, but that PlGF enhances both cytokine gene transcription and cytokine secretion induced by TLR-pathway activators in those same cells. The PlGF-enhanced TLR-7/8 response involved multiple inflammatory cytokines and chemokines, was most prominently observed with specific TLRs, and was also seen in fetal (cord blood) CD14 + cells. These findings support the hypothesis that PlGF enhances TLR-pathway-mediated inflammatory responses in human mononuclear phagocytes, and provide a potential mechanism for virus-mediated morbidity and mortality in pregnancy.
| MATERIALS AND METHODS

| Reagents
R848 (ALX-420-038, TLR-7/8) was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Lipopolysaccharide (LPS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). PlGF-1 was purchased from PeproTech (Rocky Hill, NJ, USA) and ProSpec (Ness-Ziona, Israel).
PlGF-2, PlGF-3, and VEGF-A(151) were purchased from PeproTech. CCAACAGTTCCCCAGGG. All were purchased from Thermo Fisher.
| Primary cells
| Quantification of mRNA decay
Actinomycin D (5 μg/mL, Sigma-Aldrich) was added to cells pretreated for 4 or 6 hours with 3 μm R848, with or without 250 ng/mL PlGF-1.
Total RNA was prepared at regular time intervals thereafter as described. TNF mRNA was quantified using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
| Immunoassays
| Immunoblotting
Immunoblot analyses were performed as described previously.
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| Statistical analysis
Statistical analyses were performed using a two-tailed Student t test.
A P value of ≤.05 was considered statistically significant. Unless otherwise specified, data are presented as mean values, with error bars representing the standard error of the mean (SEM) of these values. R848 treatment compared to R848 alone (P<.01, Fig. S1B ). As expected, Thus, the PlGF-1 isoform selectively enhances TLR-7/8 induced TNF secretion.
| RESULTS
|
PlGF-1 is known to bind and activate the vascular endothelial growth factor receptor-1 (VEGFR-1), 43 and in contrast to vascular endothelial growth factor receptor-2, VEGFR-1 is expressed on the cell surface of monocytes. 44, 45 As VEGF-A is also reported to activate VEGFR-1, 43 we tested the ability of VEGF-A to enhance R848-mediated TNF secretion in primary CD14 + cells. There was no effect of VEGF-A on R848-mediated TNF secretion (Fig. S2B) . Therefore, there is differential enhancement of R848-mediated TNF production by the VEGFR-1 ligands.
| PlGF-1 does not influence responsiveness to all TLR ligands
We next determined whether PlGF-1 could also enhance the production of TNF mediated by other TLR agonists, and whether this "PlGF/ TLR" effect was specific to the endosomally located TLRs (TLR-7, -8, 
| PlGF-1 enhances TNF production by cord blood CD14 + cells in response to TLR-7/8 but not TLR-4 agonists
In addition to the increased risk of maternal morbidity, the 2009 H1N1 pandemic was also associated with an increased risk of fetal morbidity and mortality. 8, 46 Consequently, we sought to determine whether PlGF-1 could also modulate the TLR responsiveness of fetal monocytes, using cord blood CD14 + cells obtained from term deliveries as a surrogate, and focused on TLR-7/8 and TLR-4 ligands given the differential responses to these ligands seen in adult CD14 + cells.
While absolute levels of TNF protein secreted by cord blood mononuclear phagocytes were reduced, compared to adult CD14 + cells (Fig. S4) , cord blood CD14 + cells exposed to PlGF-1 and R848 produced significantly more TNF than they did after exposure to R848 alone ( Figure 3 ). Additionally, as was the case with adult monocytes, there was either no or minimal enhancement in LPS-induced TNF production by PlGF-1 in cord blood CD14 + cells.
| PlGF-1 enhances the magnitude and duration of TLR-7/8-mediated TNF gene expression
Seeking to determine molecular mechanisms involved in the PlGF effect, we next sought to define the differential kinetics of the induced TNF response and to identify the degree to which transcriptional and post-transcriptional mechanisms were involved. In kinetic studies of primary cells treated with PlGF-1 and/or R848, we determined that PlGF-1 enhances both the magnitude and duration of the TNF response, with equivalent increases in unspliced ( Figure 4A ) and spliced ( Figure 4B ) TNF mRNA, and TNF protein ( Figure 4C ). PlGF-1 also prolonged the duration of TNF gene expression compared to CD14 + cells treated with R848 alone (Fig. S5A,B) . While this increase in total TNF mRNA could reflect enhanced transcription or mRNA stability, the increase in unspliced pre-TNF mRNA supports our hypothesis that the PlGF effect is due to increased gene transcription. To ensure that PlGF-1 did not function to stabilize TNF mRNA, we performed actinomycin D chase experiments. Primary cells were treated with PlGF-1 in combination with R848, or in some experiments, the addition of PlGF-1 and R848 was staggered so that one factor was added 2 hours before the other, followed by actinomycin D treatment. The results of these experiments were very similar regardless of the order of addition of PlGF-1 and R848. PlGF-1 did not increase the TNF mRNA half-life ( Figure 4D ), compatible with a transcriptional effect of PlGF- Figure 5A ,B).
While TNF protein levels peaked after 6 hours of exposure to R848
with and without PlGF-1, protein levels of cytokines including IL-8, IL-6, MIP-1 alpha, MIP-1 beta, and MCP-1 continued to increase in a "second wave" at 24 hours compared to 6 hours ( Figure 5C ). We confirmed these results at the transcript level and determined that R848-induced expression of IL-8 (average 1.51-fold, four independent experiments), IL-1β (average 1.31-fold, three independent experiments), IL-6 (average 1.70-fold, two independent experiments), MIP-1 alpha (average 1.25-fold, two independent experiments), and MIP-1 beta (average 1.58-fold, two independent experiments, P=.0969 for second replicate) mRNA was also significantly enhanced by PlGF-1 ( Figure 5D ,E). These results provide evidence that the PlGF/TLR interaction enhances the production of a broad array of inflammatory cytokines, and that this second wave of inflammatory cytokines continues to increase at 24 hours.
| Enhancement of TLR-7/8-mediated inflammatory cytokine production by PlGF-1 is independent of autocrine TNF production
Given the known role of TNF as a "master-regulator" of inflammatory cytokine production, 47 we tested the idea that the production of this "second wave" of inflammatory cytokines (all of which can be induced by TNF) was, in fact dependent upon autocrine TNF activity. IL-8, IL-1β) ( Figures 6A,B and S6A,B) . Thus, the second wave of cytokine production is independent of autocrine TNF. F I G U R E 5 PlGF-1 enhances TLR-7/8-mediated inflammatory cytokine production in CD14 + primary cells. CD14 + cells plated at 50 000/ mL were cultured in the presence of 3 μm R848, 250 ng/mL PlGF-1, or the combination. For protein quantification, cells were cultured for 6 h or 24 h, and conditioned culture media was analyzed for inflammatory cytokine production by Luminex multiplex arrays. Results shown as the mean ± SEM for a representative experiment (A, C), and as the mean fold change ± SEM in TNF protein for R848 plus PlGF-1 relative to R848 alone, for all replicate experiments (B), n=2 biologic replicates. (D, E) For messenger RNA (mRNA), cells were plated at 500 000 CD14 + cells/ mL and cultured for 4 h followed by RNA isolation. Cytokine transcript levels were measured using real-time quantitative reverse transcription polymerase chain reaction and normalized to levels of 18S rRNA. Shown is the mean ± SEM of a representative experiment (D), as well as the mean fold change ± SEM in mRNA for R848 plus PlGF-1 relative to R848 alone (E), for interleukin (IL)-8 mRNA (four biologic replicates), IL-1β (three biologic replicates), and IL-6, MIP-1 alpha, and MIP-1 beta mRNA (two biologic replicates for each) . *P < .05
| Activation of IKK-alpha/beta is required for the PlGF/TLR effect
As TLR pathways activate the IkappaB kinase (IKK) complex, which controls the nuclear localization and activation of nuclear factorkappaB, 49, 50 we reasoned that PlGF-1 might enhance the activation Figure 8D ). Therefore, we hypothesize that PlGF-1 enhances the receptivity of the canonical TLR pathway resulting in hyperactivation of IKK. disparate conditions do share in common a higher than normal risk of morbidity from viral-mediated inflammatory infections. PlGF is highly expressed in the human placenta throughout gestation and may serve two key functions: controlling the growth and differentiation of trophoblasts and serving as a paracrine factor for placental angiogenesis. [53] [54] [55] While some studies suggest that PlGF is not required for normal vascular development (knockout mice exhibit normal development and viability without an aberrant phenotype), 56 it does seem to be required to execute a normal angiogenic response during pathologic conditions such as ischemia. 56, 57 In addition, PlGF is also known to stimulate the growth, migration, and survival of endothelial cells 56, 58 and is a chemo-attractant for macrophages.
| DISCUSSION
45,59
Pathologically low PlGF levels have been shown to associate with, and predict for, the development of preeclampsia. 10, 60, 61 While preeclampsia has also been described as an inflammatory syndrome, including evidence for aberrant activation of mononuclear phagocytes, the exact mechanisms responsible for this pathologically enhanced state of innate immune activation remain unclear. 26 And while specific infections have been linked with an increased potential risk for preeclampsia, this risk does not apply to all infectious stimuli. 62 Consequently, whether preeclampsia is directly linked to infections and TLR-pathway activation is also unknown. Here, we have determined that PlGF contributes to the activation state of primary human mononuclear phagocytes but that PlGF's effect requires the simultaneous activation of specific TLR pathways. Because PlGF is produced by 
| Angiogenic stimuli and inflammation
Increasing evidence supports a functional link between angiogenic stimuli and inflammatory responses, via the production of chemokines, cytokines, and growth factors, and particularly occurring in pathologic conditions. 28, 29, 63, 64 One of these factors, PlGF, is known to enhance IL-1β, IL-8, and MCP-1 transcript numbers in peripheral blood mononuclear cells (PBMCs) of healthy subjects; these PlGF-inducible genes were also expressed at high levels in PBMCs from subjects with sickle cell disease. 30, 31 However, these studies 
| TLR pathways influenced by PlGF
The innate immune response involves a diversity of TLR receptors and pathogen-associated molecular patterns (PAMPs) recognized by these receptors. We determined that PlGF enhanced TLR-mediated TNF production, or induced TNF production in combination with TLR agonists (where there was no TNF production with TLR agonists alone), for the majority of human TLR receptors. We found the highest levels of secreted TNF in response to PlGF-1 and TLR-7/8 stimulation of mononuclear phagocytes. However, while the absolute TNF values were greatest with TLR-7/8, we found the greatest fold change in TNF protein, comparing PlGF-1 with TLR agonist vs TLR agonist alone, in response to TLR-2 stimulation. The TLR-2 receptor recognizes a wide variety of ligands, including cell-wall components, lipoproteins and lipopeptides of Gram-positive bacterial and mycobacterial origin, and yeast zymosan. 65 It can bind to these PAMPs in concert with TLR-1 or TLR-6. Interestingly, while there was also evidence of a PlGF effect with the TLR-1/2 agonist (PAM3cSK4) and the TLR-6/2 agonist (FSL-1), the greatest TNF response was seen with the TLR-2 agonist HKLM. Whether this differential TLR-2 effect is due to specific properties of the ligand is unknown. For example, the more robust response to the Gram-positive bacterium Listeria monocytogenes (HKLM), than to the diacylated (FSL-1) 66 or triacylated (PAM3cSK4) 67 lipopeptides, might be the result of PlGF's capacity to influence the structure or function of TLR-2. Alternatively, PlGF might influence the interaction of TLR-2 with cooperative factors (eg, TLR-1 or TLR-6).
We also observed that neither of the specific TLR-7 nor TLR-8 ligands were as potent as the TLR-7/8 ligand R848. We hypothesize this may be due to synergistic activity of both TLRs, because when
Imiquimod (TLR-7) was combined with ssRNA40 (TLR- 
| TLR-4 activation is not influenced by PlGF
Our finding that PlGF does not enhance TLR-4 activation is more certain, and intriguing. We believe that this observation will aid in future studies seeking to identify specific signaling pathways that permit PlGF to enhance inflammatory cytokine production. For example, LPS is known to activate both canonical MyD88/IRAK pathways and non-canonical (MyD88-independent) pathways. 73 One possibility is that the non-canonical pathway (activated by LPS F I G U R E 6 Enhancement of TLR-7/8-mediated inflammatory cytokine production by PlGF-1 is independent of autocrine TNF production. 500 000 CD14 + cells/mL were pre-treated for 1-h with sTNFR1 0.1 or 1 μg/mL, followed by 4 h of culture with 3 μm R848 ± 250 ng/mL PlGF-1. Total RNA was isolated at time 0 and after 5 h total culture. IL-8 (A) and IL-1β (B) messenger RNA (mRNA) was measured using real-time quantitative reverse transcription polymerase chain reaction and normalized to levels of 18S rRNA. Shown is the mean ± SEM, representative of two replicate experiments Whether PlGF is activating non-canonical or alternate inflammatory signaling pathways, or instead functioning to inhibit the inhibitors of TLR-mediated inflammatory responses, remains to be determined. Nonetheless, taken together our results suggest that the effect of PlGF on priming of the innate immune system may be broader than we had initially anticipated (eg, beyond TLR-7/8), and may involve maternal immune responses to diverse infectious stimuli.
| PlGF isoforms and VEGFR-1 ligands
We also determined that of the different VEGFR-1 ligands, only the PlGF-1 isoform was able to enhance TLR-mediated TNF expression, although the mechanism responsible for this isoform specificity is unclear. In pregnancy, expression of the PlGF isoform transcripts has been demonstrated in normal human trophoblasts and umbilical vein endothelial cells. 74 While there are few studies focused on circulating levels of the different PlGF isoforms, maternal levels of serum PlGF-1 and PlGF-2 are highly correlated. That is, both increase with gestational age and have similar predictive value for late preeclampsia and delivery of small for gestational age offspring. 75 Similarly, in conditions characterized by aberrant expression of PlGF, such as rheumatoid arthritis, both the PlGF-1 and PlGF-2 isoforms increased survival, migration, and invasiveness of rheumatoid fibroblast-like synoviocytes, 76 although differences in PlGF-1 and PlGF-2 expression have been described in the setting of malignancy (eg, breast cancer). 77 The role of the VEGFR-1 ligand VEGF-A in inflammatory events is less clear. In pregnancy, while circulating VEGF-A levels normally increase, 78 maternal VEGF levels are decreased in preeclampsia. We found no evidence of an enhancing effect of VEGF-A on TLR-7/8-mediated TNF production; instead, we found higher levels of VEGF-A may contribute to decreased TNF secretion in TLR-7/8-stimulated monocytes. Whether the comparative differential activities we describe result from differences in receptor-binding affinity remains to be determined. 
| PlGF influences multiple cytokines and chemokines
PlGF influences TLR agonist-dependent production of a broad array of inflammatory cytokines, including the expression of IL-1β, IL-6, IL-8, MIP-1 alpha, MIP-1 beta, and MCP-1, at both the mRNA and protein levels. Interestingly, a major effect of PlGF involved the duration of the production of these pro-inflammatory cytokines, which in contrast to TNF, continued to increase at 24 hours, suggesting that PlGF enhances the production, as well as prolongs the duration of activation, of numerous inflammatory cytokines. It was reasonable to consider that TNF might trigger an autocrine pathway responsible for the prolonged and durable production of inflammatory cytokines under these conditions, however we found that it did not. That is, blocking TNF signaling did not alter the production of other inflammatory cytokines (eg, IL-8, IL-1β). These results suggest a broader effect of PlGF on inflammatory cytokine production, including an early enhancement of TNF production, and a subsequent, more durable TNF-independent enhancement of inflammatory cytokine expression. 
| PlGF/TLR signaling
| PlGF responsiveness of cord blood monocytes
In this study, we focused on adult peripheral blood CD14 Therefore, whether PlGF contributes to a priming effect in pregnancy is not a settled issue.
In partial agreement with the findings of Levy et al. 81 and Marchant et al., 82 we found decreased absolute TNF protein levels produced by cord blood mononuclear phagocytes, compared to adult monocytes, at all dose levels of R848 and LPS tested, with or without PlGF.
Despite these differences in total TNF secretion, in our assays we did identify evidence of a PlGF effect. That is PlGF enhanced TLR-7/8 but not TLR-4-mediated TNF production in cord blood monocytes, similar our findings in adult mononuclear phagocytes.
During the H1N1 pandemic, not only was pregnancy associated with an increased risk of death, but mortality among H1N1 infected pregnant women was associated with an increased prevalence of inflammatory complications (eg, ARDS). [4] [5] [6] Work of Cardenas et al. 83 has
demonstrated that viral infection of the placenta induces inflammatory responses in the fetus, without fetal transmission of the virus.
Additionally, such viral infections can also lead to sensitization to bacterial products, implicating the viral-induced activation of the immune response in a process affecting both the mother and fetus. Thus, it is reasonable to speculate that for those women infected with H1N1 who did also develop concurrent bacterial infections, the activation state imposed by the viral infection itself would be an important element in the clinical outcome. We therefore hypothesize that the PlGF/ TLR effect may contribute to an exaggerated pathologic inflammatory response to infectious stimuli in both maternal and fetal cells, accounting for both maternal and fetal morbidity in women challenged with specific viral infections during pregnancy (eg, influenza).
| CONCLUSION
Taken together, the results of our studies indicate that PlGF, levels of which peak during the third trimester of pregnancy and precisely the time at which pregnant women are particularly susceptible to viral-mediated morbidity, may contribute directly to an exaggerated 
